Skip to main content
. 2022 Aug 26;17(9):2559–2571. doi: 10.1021/acschembio.2c00497

Figure 5.

Figure 5

Adjuvanted nanocarrier formulation skews neonatal immunity toward a type 1 response. Together, cGAMP and CL075 encapsulating PSs alter rHA-specific Th1 polarization and overcome the inability of the infant immune system to mount a type 1 immunity and tune the degree of immune response enhancement. (A) The magnitude of rHA-specific IgG2c titers (at DOL 21), Th1 polarization, TFH, and GC B cell responses (DOL 26) is shown in a radar plot as a fold-change over cGAMP-PS-immunized group (black line). Statistical comparison was performed either using one-way ANOVA or nonparametric Kruskal-Wallis test corrected for multiple comparisons; *p < 0.033, **p < 0.002, ***p < 0.001 (n = 5–12 per group). The study was inclusive of two independent repeats. (B) Tunable aspects of different formulations when small-molecule agonists are encapsulated in PEG-b-PPS nanocarriers.